Study of surufatinib, serplulimab, chemo for neuroendocrine carcinoma
Part of Cancer clinical trials.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of neuroendocrine carcinoma that started outside the lung (including mixed tumors with at least 30% neuroendocrine cells).
- You have not had any previous systemic therapy for this cancer.
- You are 18 years or older.
- You have at least one tumor that can be measured on scans.
- Your overall health is good (ECOG score 0 or 1).
- Your major organs (bone marrow, liver, kidneys) are functioning well enough, based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This study tests a combination of two medications (surufatinib and serplulimab) for advanced solid tumors that have stopped responding to standard treatment and show special neuroendocrine markers. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of three drugs (surufatinib, serplulimab, and standard chemotherapy) as a first treatment for advanced solid tumors that have neuroendocrine differentiation. The goal is to see if this combination helps control the cancer better than standard therapy alone.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.